Analyst Price Targets — PEPG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 13, 2026 12:40 pm | Laura Chico | Wedbush | $4.00 | $1.62 | TheFly | PepGen price target lowered to $4 from $5 at Wedbush |
| February 18, 2026 12:25 pm | Debjit Chattopadhyay | Guggenheim | $7.00 | $6.79 | TheFly | PepGen price target raised to $7 from $6 at Guggenheim |
| October 28, 2025 11:16 am | Andrew Fein | H.C. Wainwright | $18.00 | $5.28 | TheFly | PepGen price target raised to $18 from $12 at H.C. Wainwright |
| September 25, 2025 5:06 pm | — | Stifel Nicolaus | $12.00 | $5.88 | TheFly | PepGen price target raised to $12 from $9 at Stifel |
| September 25, 2025 12:03 pm | — | Wedbush | $9.00 | $5.88 | TheFly | PepGen price target raised to $9 from $7 at Wedbush |
| December 21, 2022 6:26 am | — | H.C. Wainwright | $26.00 | $14.51 | Benzinga | HC Wainwright & Co. Initiates Coverage On PepGen with Buy Rating, Announces Price Target of $26 |
| November 10, 2022 1:35 pm | — | Leerink Partners | $33.00 | $12.50 | Benzinga | SVB Leerink Maintains Outperform on PepGen, Lowers Price Target to $33 |
Latest News for PEPG
ADAR1 Capital Management LLC acquired a new position in PepGen, Inc. (NASDAQ: PEPG) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 2,591,085 shares of the company's stock, valued at approximately $4,664,000. ADAR1 Capital Management LLC owned approximately 3.74% of PepGen as of
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the
[url="]PepGen Inc.[/url] (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of tran
BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights.
BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PEPG.
U.S. House Trading
No House trades found for PEPG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.